These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1751205)

  • 1. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
    Besarab A; Golper TA
    ASAIO Trans; 1991; 37(3):M395-6. PubMed ID: 1751205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Pais MJ; Gaspar A; Santana A; Bruges M; Simões J
    Perit Dial Int; 1993; 13 Suppl 2():S541-3. PubMed ID: 8399660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin.
    Besarab A; Besarab FM; Miller D
    ASAIO Trans; 1991; 37(3):M181-2. PubMed ID: 1751101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of hypertension is better during hemodialysis than during continuous ambulatory peritoneal dialysis in ESRD patients.
    Velasquez MT; Lew SQ; von Albertini B; Mishkin GJ; Bosch JP
    Clin Nephrol; 1997 Dec; 48(6):341-5. PubMed ID: 9438091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis].
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Pol; 1995 Dec; 70(12):1023-8. PubMed ID: 8649941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous recombinant human erythropoietin in patients on CAPD.
    Lye WC; Lee EJ
    Adv Perit Dial; 1991; 7():285-7. PubMed ID: 1680447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once weekly subcutaneous administration of recombinant erythropoietin in children treated with CAPD.
    Goldraich I; Goldraich N
    Adv Perit Dial; 1992; 8():440-3. PubMed ID: 1361843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis.
    Lai PC; Wu MS; Huang JY; Huang CC; Leu ML
    Changgeng Yi Xue Za Zhi; 1994 Jun; 17(2):105-12. PubMed ID: 8069732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: comparison between intravenous and intraperitoneal administration.
    Nasu T; Mitui H; Shinohara Y; Hayashida S; Ohtuka H
    Perit Dial Int; 1992; 12(4):373-7. PubMed ID: 1420496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia of chronic renal failure: treatment with erythropoietin.
    Navarro M; Alonso A; Avilla JM; Espinosa L
    Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does parathyroid hormone affect erythropoietin therapy in dialysis patients?
    Al-Hilali N; Al-Humoud H; Ninan VT; Nampoory MR; Puliyclil MA; Johny KV
    Med Princ Pract; 2007; 16(1):63-7. PubMed ID: 17159367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal administration of recombinant human erythropoietin.
    Frenken LA; Struijk DG; Coppens PJ; Tiggeler RG; Krediet RT; Koene RA
    Perit Dial Int; 1992; 12(4):378-83. PubMed ID: 1420497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis.
    Huang TP; Lin CY
    Am J Nephrol; 1995; 15(4):312-7. PubMed ID: 7573189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better response to s.c. erythropoietin in CAPD than HD patients.
    Stegmayr BG
    Scand J Urol Nephrol; 1997 Apr; 31(2):183-7. PubMed ID: 9165584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
    Aufricht C; Balzar E; Steger H; Lothaller MA; Frenzel K; Kohlhauser C; Kiss H; Khoss AE; Kernova T
    Acta Paediatr; 1993 Nov; 82(11):959-62. PubMed ID: 8111178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.